Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P33897: Variant p.Arg660Trp

ATP-binding cassette sub-family D member 1
Gene: ABCD1
Feedback?
Variant information Variant position: help 660 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Tryptophan (W) at position 660 (R660W, p.Arg660Trp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to large size and aromatic (W) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In ALD; CALD, ALMD and AS-types. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 660 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 745 The length of the canonical sequence.
Location on the sequence: help EGKIFQAAKDAGIALLSITH R PSLWKYHTHLLQFDGEGGWK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         EGKIFQAAKDAGIALLSITHRPSLWKYHTHLLQFDGEGGWK

Mouse                         EGKIFQAAKDAGIALLSITHRPSLWKYHTHLLQFDGEGGWK

Rat                           EGKIFQAAKDAGISLLSITHRPSLWKYHTHLLQFDGEGGWK

Zebrafish                     EGKIFEAAKDAGISLLSITHRPSLWKYHSHLLQFDGEGGWR

Drosophila                    ESSIYEIAKGMGITLLTITHRPTLWKYHTHILEFDGLGNWQ

Slime mold                    EERVYYVAKELGITIISVGHRISLLKYHSTLLRFDKDKNWY
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 745 ATP-binding cassette sub-family D member 1
Domain 474 – 700 ABC transporter
Region 658 – 745 Required for homodimerization



Literature citations
Spectrum of mutations in the gene encoding the adrenoleukodystrophy protein.
Ligtenberg M.J.L.; Kemp S.; Sarde C.-O.; van Geel B.M.; Kleijer W.J.; Barth P.G.; Mandel J.-L.; van Oost B.A.; Bolhuis P.A.;
Am. J. Hum. Genet. 56:44-50(1995)
Cited for: VARIANTS ALD CYS-104; ASN-149; PRO-152; HIS-163; HIS-194; PRO-220; ARG-266; HIS-389; GLY-609; LYS-609; CYS-617 AND TRP-660; Altered expression of ALDP in X-linked adrenoleukodystrophy.
Watkins P.A.; Gould S.J.; Smith M.A.; Braiterman L.T.; Wei H.M.; Kok F.; Moser A.B.; Moser H.W.; Smith K.D.;
Am. J. Hum. Genet. 57:292-301(1995)
Cited for: VARIANTS ALD GLU-276; ASP-291; GLU-291 DEL; PRO-342; HIS-389; GLN-401; GLN-591; LEU-606; HIS-617; THR-626; HIS-629 AND TRP-660; Mutational analysis of patients with X-linked adrenoleukodystrophy.
Kok F.; Neumann S.; Sarde C.-O.; Zheng S.; Wu K.-H.; Wei H.-M.; Bergin J.; Watkins P.A.; Gould S.; Sack G.; Moser H.; Mandel J.-L.; Smith K.D.;
Hum. Mutat. 6:104-115(1995)
Cited for: VARIANTS ALD CYS-104; THR-141; PRO-182; TRP-277; HIS-389; SER-512; LYS-566; LEU-606; HIS-617 AND TRP-660; Molecular analysis of X-linked adrenoleukodystrophy patients.
Yasutake T.; Yamada T.; Furuya H.; Shinnoh N.; Goto I.; Kobayashi T.;
J. Neurol. Sci. 131:58-64(1995)
Cited for: VARIANTS ALD SER-512; LEU-534 AND TRP-660; Mutational and protein analysis of patients and heterozygous women with X-linked adrenoleukodystrophy.
Feigenbaum V.; Lombard-Platet G.; Guidoux S.; Sarde C.-O.; Mandel J.-L.; Aubourg P.;
Am. J. Hum. Genet. 58:1135-1144(1996)
Cited for: VARIANTS ALD LEU-98; ILE-105; TRP-108; ARG-116; SER-148; VAL-200; GLY-221; LEU-263; THR-294; SER-512; TRP-518; TRP-522; ARG-560; PRO-606 AND TRP-660; Mutational analysis and genotype-phenotype correlation of 29 unrelated Japanese patients with X-linked adrenoleukodystrophy.
Takano H.; Koike R.; Onodera O.; Sasaki R.; Tsuji S.;
Arch. Neurol. 56:295-300(1999)
Cited for: VARIANTS ALD SER-148; ASN-200; ASP-214; ARG-266; LYS-271; CYS-296; TRP-401; VAL-507; GLN-518; SER-540; ARG-544; TRP-591; LEU-606 AND TRP-660; Identification of novel SNPs of ABCD1, ABCD2, ABCD3, and ABCD4 genes in patients with X-linked adrenoleukodystrophy (ALD) based on comprehensive resequencing and association studies with ALD phenotypes.
Matsukawa T.; Asheuer M.; Takahashi Y.; Goto J.; Suzuki Y.; Shimozawa N.; Takano H.; Onodera O.; Nishizawa M.; Aubourg P.; Tsuji S.;
Neurogenetics 12:41-50(2011)
Cited for: VARIANTS ALD LEU-108; SER-148; ASP-214; PRO-254; ARG-266; LYS-271; ARG-277; TRP-401; GLN-518; TRP-518; SER-540; ARG-544; LEU-560; LYS-609 AND TRP-660;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.